Logo
JNJ logo
Johnson & Johnson
JNJ
271.41 (0.44%) 1.19
Health Care
Pharmaceuticals
Johnson & Johnson together with its subsidiaries engages in the research and development manufacture and sale of a range of products in the healthcare field worldwide. It operates in two segments Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas such as oncology immunology neuroscience pulmonary hypertension infectious diseases and cardiovascular and metabolism distributed through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery orthopedic cardiovascular and vision fields distributed through wholesalers hospitals and retailers and used in the professional fields by physicians nurses hospitals eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction trauma spine sports related injuries and others as well as open laparoscopic and robotic surgical procedures; instrumentation energy devices stapling systems wound closure biosurgery products and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick New Jersey.

Quality Checklist 6/8

5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $654.07(B)
EV: $682.35(B)
Total Equity: $84.97(B)
Earnings date: Oct-13-2026
P/E: 31.05
Forward P/E: 24.56
P/FCF: 29.37
P/S: 6.67
P/B: 7.69
EPS: $8.7
EPS (fwd): $11.1
FCF/share: $9.2
Revenue/share: $40.7
Book value/share: $35.3
ROIC: 21.7%
ROA: 13.5%
ROE: 33.6%
Debt/Equity: 0.58
Current Ratio: 1.10
Gross margin: 68.1%
Operating margin: 26.2%
Net margin: 21.5%
Dividend/share: $5.2
Div. yield: 1.93%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$97.93(B)
Gross profit$66.73(B)
EBITDA$34.87(B)
Net income$21.04(B)
Gross margin68.1%
Operating margin26.2%
Net margin21.5%
Shares outstanding2.41(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$201.06(B)
Current assets$59.77(B)
Total liabilities$116.09(B)
Current liabilities$54.90(B)
Cash & Short-term inv.$20.76(B)
Long-term debt$37.34(B)
Total intangibles$96.71(B)
PP&E$23.58(B)

Cash flow (TTM)

CFOCFICFF
FCF$22.24(B)
CapEx$-5.36(B)
Dividends paid$-12.62(B)
Stock issued$4.39(B)
Stock repurchased$-8.07(B)
Stock-based comp.$1.41(B)
Debt issued$18.38(B)
Debt repaid$-19.95(B)

Per share data (TTM)

Price: $271
Revenue: $40.7 (6.7x | 15.0%) Gross profit: $27.7 (9.8x | 10.2%) Earnings: $8.74 (31.1x | 3.2%)
FCF: $9.24 (29.4x | 3.4%) Stock-based Comp.: $0.59 (462.6x | 0.2%) CapEx.: $2.23 (121.9x | 0.8%) Dividend: $5.24 (51.8x | 1.9%)
Total Assets: $83.4 (3.3x | 30.7%) Total Liabilities: $48.2 (5.6x | 17.7%) Book Value: $35.3 (7.7x | 13.0%) Cash & ST inv.: $8.61 (31.5x | 3.2%) Debt: $15.5 (17.5x | 5.7%)
Earnings FY+1: $11.1 (24.6x | 4.1%) Earnings FY+2: $12.3 (22.0x | 4.5%) Earnings FY+3: $15.3 (17.7x | 5.7%) Earnings FY+4: $18.1 (15.0x | 6.7%) Earnings FY+5: $20.6 (13.1x | 7.6%)
FCF FY+1: $9.98 (27.2x | 3.7%) FCF FY+2: $11.3 (24.1x | 4.1%) FCF FY+3: $12.4 (21.8x | 4.6%) FCF FY+4: $14.0 (19.4x | 5.2%) FCF FY+5: $14.5 (18.7x | 5.4%)

Summary

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact